Report from the 34th annual meeting of the American Society of Hematology, December 4-8, 1992.
Markman
M
M
Cleveland Clinic Cancer Center, Ohio.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D007938:Leukemia / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008495:Medical Oncology; D009101:Multiple Myeloma / Q000188:drug therapy; D012955:Societies, Medical
D000970:Antineoplastic Agents; D016898:Interferon-alpha; D003561:Cytarabine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide